Naturalendo Tech Co., Ltd. (KOSDAQ:168330)
2,125.00
+5.00 (0.24%)
At close: Oct 16, 2026
Naturalendo Tech Revenue
Naturalendo Tech had revenue of 6.15B KRW in the quarter ending June 30, 2026, with 21.81% growth. This brings the company's revenue in the last twelve months to 22.79B, up 0.93% year-over-year. In the year 2025, Naturalendo Tech had annual revenue of 22.23B, down -0.16%. That makes Naturalendo Tech the 34,728th largest company in the world by revenue and 2,218th in South Korea.
Revenue (ttm)
22.79B
Revenue Growth
+0.93%
P/S Ratio
2.94
Revenue / Employee
274.61M
Employees
83
Market Cap
67.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.23B | -36.68M | -0.16% |
| Dec 31, 2024 | 22.26B | 3.47B | 18.48% |
| Dec 31, 2023 | 18.79B | 4.84B | 34.69% |
| Dec 31, 2022 | 13.95B | -744.85M | -5.07% |
| Dec 31, 2021 | 14.70B | 1.45B | 10.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 131.54B |
| Choong Ang Vaccine Laboratory | 39.19B |
| BIO-FD&C | 19.53B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.57B |
| EyeGene | 4.48B |
| SunBio,Inc. | 2.17B |
| NovMetaPharma | 1.30B |